...
首页> 外文期刊>International Journal of Pharmaceutics >Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect.
【24h】

Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect.

机译:装载多西他赛的固体自纳米乳化药物递送系统(SNEDDS)的开发可增强化疗效果。

获取原文
获取原文并翻译 | 示例
           

摘要

The main purpose of this study was to investigate the potential of self-nano-emulsifying drug delivery system (SNEDDS) in improving the bioavailability of docetaxel (DCT) and its chemotherapeutic effect. The DCT-loaded SNEDDS was prepared by employing rational blends of capryol 90, labrasol, and transcutol HP using ternary phase diagram. The liquid nano-emulsion was spray-dried into solid SNEDDS (D-SNEDDS) using an inert porous carrier, colloidal silica. The optimized formulation was characterized in terms of physico-chemical and pharmacokinetic parameters. Furthermore, anti-tumor efficacy of D-SNEDDS was compared with commercial marketed product, Taxotere(?). The various compositions of SNEDDS were screened and found optimal at a volume ratio of 10/75/15 for capryol 90, labrasol, and transcutol HP, respectively. We observed a high oral bioavailability of 17% DCT for D-SNEDDS than compared to only 2.6% for pure DCT solution. Notably, D-SNEDDS exhibited an augmented anti-tumor efficacy with a reduced toxicity profile when compared with intravenously administered Taxotere(?), the commercialized formulation of DCT. Taken together, D-SNEDDS could be a potential candidate for an oral dosage form of DCT with enhanced antitumor activity and reduced toxicity.
机译:这项研究的主要目的是研究自我纳米乳化药物递送系统(SNEDDS)在提高多西紫杉醇(DCT)的生物利用度及其化学治疗效果方面的潜力。负载DCT的SNEDDS是通过使用三元相图采用辛酸90,拉布拉索尔和反式角豆酚HP的合理混合物制备的。使用惰性多孔载体胶体二氧化硅将液体纳米乳液喷雾干燥为固体SNEDDS(D-SNEDDS)。根据理化和药代动力学参数对优化配方进行了表征。此外,将D-SNEDDS的抗肿瘤功效与市售产品Taxotere(β)进行了比较。筛选了各种SNEDDS组合物,发现它们的体积比分别为辛酸90,拉布拉索尔和transcutol HP最佳,为10/75/15。我们观察到D-SNEDDS的口服生物利用度为17%,而纯DCT溶液仅为2.6%。值得注意的是,与静脉内施用的DCT商业化制剂Taxotere(?)相比,D-SNEDDS表现出增强的抗肿瘤功效,且毒性降低。两者合计,D-SNEDDS可能是DCT口服剂型的潜在候选者,具有增强的抗肿瘤活性和降低的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号